Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women

被引:253
作者
Wells, G
Tugwell, P
Shea, B
Guyatt, G
Peterson, J
Zytaruk, N
Robinson, V
Henry, D
O'Connell, D
Cranney, A
机构
[1] McMaster University, Department of Clinical Epidemiology, Hamilton, Ont. L8N 3Z5
关键词
D O I
10.1210/er.2001-5002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To review the effect of hormone replacement therapy (HRT) on bone density and fractures in postmenopausal women. Data Source: We searched MEDLINE and EMBASE from 1966 to 1999, the Cochrane Controlled Register, citations of relevant articles, and proceedings of international meetings for eligible randomized controlled trials. We contacted osteoporosis investigators to identify additional studies, and primary authors for unpublished data. Study Selection: We included 57 studies that randomized postmenopausal women to HRT or a control (placebo or calcium/vitamin D) and were of at least 1 yr in duration. Seven of these studies reported fractures. Data Abstraction: For each study, three independent reviewers assessed the methodological quality and abstracted the data. Data Synthesis: HRT showed a trend toward reduced incidence of vertebral fractures [relative risk (RR) 0.66, 95% confidence interval (CI) 0.41-1.07; 5 trials] and nonvertebral fractures (RR 0.87, 95% CI 0.71-1.08; 6 trials). HRT had a consistent effect on bone mineral density (BMD) at all sites. The difference between HRT and control in the percent change in bone density at 2 yr was 6.76 (5.83, 7.89; 21 trials) at the lumbar spine and 4.53 (3.68, 5.36; 14 trials) and 4.12 (3.45, 4.80; 9 trials) at the forearm and femoral neck, respectively. Conclusions: HRT has a consistent, favorable and large effect on bone density at all sites. The data show a nonsignificant trend toward a reduced incidence in vertebral and nonvertebral fractures.
引用
收藏
页码:529 / 539
页数:11
相关论文
共 90 条
  • [1] Cytokines and T-lymphocyte subsets in healthy post-menopausal women: Estrogen retards bone loss without affecting the release of IL-1 or IL-1ra
    Abrahamsen, B
    Bendtzen, K
    BeckNielsen, H
    [J]. BONE, 1997, 20 (03) : 251 - 258
  • [2] TRANSDERMAL ESTRADIOL IN THE TREATMENT OF POSTMENOPAUSAL BONE LOSS
    ADAMI, S
    SUPPI, R
    BERTOLDO, F
    ROSSINI, M
    RESIDORI, M
    MARESCA, V
    LOCASCIO, V
    [J]. BONE AND MINERAL, 1989, 7 (01): : 79 - 86
  • [3] Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone
    Agnusdei, D
    Gennari, C
    Bufalino, L
    [J]. OSTEOPOROSIS INTERNATIONAL, 1995, 5 (06) : 462 - 466
  • [4] CALCITONIN AND ESTROGENS
    AGNUSDEI, D
    CIVITELLI, R
    CAMPOREALE, A
    GENNARI, C
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1990, 13 (08) : 625 - 630
  • [5] ESTROGEN REPLACEMENT THERAPY FOR PREVENTION OF OSTEOPOROSIS AFTER OOPHORECTOMY
    AITKEN, JM
    HART, DM
    LINDSAY, R
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1973, 3 (5879): : 515 - 518
  • [6] Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: A randomized study
    Alexandersen, P
    Riis, BJ
    Christiansen, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (09) : 3013 - 3020
  • [7] CALCIUM SUPPLEMENTATION WITH AND WITHOUT HORMONE REPLACEMENT THERAPY TO PREVENT POSTMENOPAUSAL BONE LOSS
    ALOIA, JF
    VASWANI, A
    YEH, JK
    ROSS, PL
    FLASTER, E
    DILMANIAN, FA
    [J]. ANNALS OF INTERNAL MEDICINE, 1994, 120 (02) : 97 - 103
  • [8] Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
  • [9] Hormone replacement therapy, heart disease, and other considerations
    Barrett-Connor, E
    Grady, D
    [J]. ANNUAL REVIEW OF PUBLIC HEALTH, 1998, 19 : 55 - 72
  • [10] Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0